Drug intelligence / Profile preview

VSF-173

Development stage: Phase 2
Lead developer: Vanda Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

VSF-173 is an oral small molecule drug candidate developed by Vanda Pharmaceuticals for the treatment of excessive sleepiness. It has demonstrated effects on animal sleep/wake patterns and gene expression, suggesting wake-promoting properties. The mechanism of action for VSF-173 remains undefined. Clinical studies have shown that it can improve wakefulness in models of excessive sleepiness, with efficacy similar to that observed with modafinil in narcolepsy. The drug reached Phase II clinical trials.

Beyond the preview

Go deeper on VSF-173.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSF-173.

Explore the full profile